Generex Biotechnology Corporation

Generex Biotechnology Corporation is an integrated healthcare holding company that focuses on providing end-to-end solutions for patient-centric care. Established in 1983, the company has positioned itself as a new kind of healthcare entity, extending beyond traditional models to offer support to physicians in an MSO network, as well as establishing ongoing relationships with patients to enhance the overall patient experience and access to optimal care. The company is dedicated to advancing a legacy portfolio of immune-oncology assets, medical devices, and diagnostics. Moreover, it has adopted a strategic acquisition approach, seeking out businesses that complement its existing assets, with a goal of generating immediate revenue and securing working capital. Recent acquisitions include a management services organization, a network of pharmacies, a clinical laboratory, and medical device companies with new and approved products. Generex Biotechnology's newly created subsidiary, NuGenerex Distribution Solutions (NDS), integrates its MSO network with a pharmacy network, clinical diagnostic lab, durable medical equipment company (DME-IQ), and a dedicated call center. The company has received a $750.00K Post-IPO Equity investment on 10 August 2012. The company operates within the Biopharma, Biotechnology, and Pharmaceutical industries, and is headquartered in the United States. With its commitment to reshaping the healthcare landscape, Generex Biotechnology Corporation is poised for significant growth and impact within the industry.